Candriam SCA’s Travere Therapeutics TVTX Stock Holding History

Candriam SCA’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$27.3M	Sell	461,331 -8,934	-2%	-$546K	0.12%	159
2026 Q2	$26.7M	Buy	470,265 +100,270	+27%	+$4.45M	0.12%	165
2026 Q1	$11M	Sell	369,995 -98,561	-21%	-$2.95M	0.06%	266
2025 Q4	$17.9M	Sell	468,556 -44,125	-9%	-$1.43M	0.09%	200
2025 Q3	$12.3M	Hold	512,681	–	–	0.06%	247
2025 Q2	$7.59M	Sell	512,681 -21,391	-4%	-$355K	0.04%	293
2025 Q1	$9.6M	Buy	+534,072	New	+$10.8M	0.06%	243

Other funds holding TVTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Candriam SCA's TVTX Position: Q3 2026 in Review

Candriam SCA reduced its Travere Therapeutics (TVTX) stake by 1.9% in Q3 2026, selling an estimated $546K and leaving 461,331 shares worth $27.3M. The position accounts for 0.12% of the portfolio, ranked #159.

Candriam SCA first reported a position in TVTX in Q1 2025 and has held it in 7 quarters since. 131 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

Candriam SCA held 461,331 shares of Travere Therapeutics worth $27.3M as of Q3 2026.
Candriam SCA sold 8,934 Travere Therapeutics shares in Q3 2026, an estimated $546K.
Travere Therapeutics made up 0.12% of Candriam SCA's portfolio in Q3 2026, its #159 holding.
Candriam SCA first reported a position in Travere Therapeutics in Q1 2025 and has held it in 7 quarters since.
131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.